Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA
This article was originally published in The Tan Sheet
Executive Summary
Data on aloe and cascara sagrada from the German Commission E monographs, World Health Organization reviews and the National Toxicology Program are insufficient to support the safety and efficacy of the ingredients in OTC laxatives, FDA concludes in a July 3 letter to the American Herbal Products Association
You may also be interested in...
In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware
P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.
In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware
P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.
FDA Considers Sodium Picosulfate For OTC Laxatives Monograph Inclusion
FDA has announced a call for data for safety and effectiveness information on sodium picosulfate up to 10 mg as a laxative single active ingredient